Nanoparticles For Drug Delivery Research Articles

Development, QbD-based optimisation, in-vivo pharmacokinetics, and ex-vivo evaluation of Eudragit® RS 100 loaded flurbiprofen nanoparticles for oral drug delivery.

This study aims to develop and evaluate flurbiprofen-loaded polymeric nanoparticles to achieve sustained drug release, enhancing therapeutic efficacy and minimising dosing frequency for improved patient outcomes. Flurbiprofen-loaded polymeric nanoparticles were prepared using a tubular microreactor and spray drying, optimised via Box-Behnken Design. Characterisation included particle size, encapsulation efficiency, in vitro and in vivo drug release, and techniques like FTIR, DSC, XRD, and SEM. Statistical analysis ensured robust formulation optimisation and evaluation of performance. The optimised batch of flurbiprofen-loaded polymeric nanoparticles was characterised for mean diameter, PDI, zeta potential, drug release, and EE% were found to be 306.1 ± 6.00 nm, 0.184 ± 0.02 Mw, -23.6 ± 1.51 mV, 85.46 ± 0.53% and 92.31 ± 0.84 (% w/w) respectively. Pharmacokinetic analysis further confirmed the sustained release, extending up to 12 hours and enhancing permeation compared to the pure flurbiprofen. Sustained release of flurbiprofen-loaded polymeric nanoparticles significantly enhances therapeutic effectiveness for inflammatory conditions.

Nanoparticles Combining Host‐Directed Therapeutics and Antibiotics to Boost Bacterial Killing and Overall Survival of Zebrafish Embryos Infected with Mycobacterium Marinum

AbstractThe bacterial pathogen, Mycobacterium tuberculosis (Mtb), remains a leading cause of global morbidity and mortality. Due to the complexity of the infection, the limited efficacy of antibiotics, and the increasing incidence of multi‐drug resistant strains, novel therapeutics are urgently needed. An interesting new approach is to combine antibiotics with treatments that boost the natural ability of host cells to kill the bacteria, so‐called host‐directed therapeutics (HDT). Until now, this approach has not been explored in the context of nanoparticle drug delivery, which may offer several advantages. Here, the HDT drug everolimus and the antibiotic ((S)‐2‐nitro‐6‐((5‐((4‐(trifluoromethoxy)phenyl)ethynyl)pyridin‐2‐yl)methoxy)‐6,7‐dihydro‐5H‐imidazo[2,1‐b][1,3]oxazine, drug D) are focused on. Both of these agents, drug D and everolimus, are encapsulated into one single micelle (PeptoMicelles), resulting in formulation C, and compared with micelles containing only drug D (formulation A) or everolimus (formulation B). They are tested in Mtb‐infected primary macrophages and THP‐1 cells, and in the zebrafish model for TB (Mm infection) using embryo survival analysis. The results show that formulation C, containing drug D and everolimus in one micelle, is significantly more efficient in protecting cells and zebrafish embryos against infection than all other formulations, indicating an improved therapeutic efficacy of HDTs and antibiotics in a single polymeric micelle.

Ultrasound-triggered nano delivery of lenvatinib for selective immunotherapy treatment against hepatocellular carcinoma

Although there have been remarkable advances in the treatment of hepatocellular carcinoma (HCC), the prognosis remains poor in those with advanced stage and more effective therapeutic options are urgently needed. Lenvatinib (Len), a multiple receptor tyrosine kinase inhibitor, is an emerging molecular targeted agent for HCC, whose immunomodulatory activities have been investigated. However, Len utilization is limited because of its low metabolic stability, poor bioavailability and dose-dependent toxicity, rendering its direct use insufficient for immune modulation. Stimuli-responsive nanoparticles, which are drug-targeted delivery platforms for on-demand drug release, facilitate deeper and uniform tumour penetration, providing alternative solutions to overcome current limitations. Ultrasound (US) exhibits superior tissue penetration abilities and can produce reactive oxygen species (ROS) at the tumour site to treat deeper tumours. In addition, US serves as an excellent and selective drug delivery mediator for tumour treatment. Herein, we designed US-triggered lenvatinib nanoparticles (Len-RNPs) for selective drug delivery that utilize US-triggered ROS to induce in situ oxidation reactions, resulting in nanoparticle disintegration. Len-RNPs mitigate the toxicity of Len and effectively trigger robust systemic anti-tumour immune responses in a H22 tumour model, resulting in a tumour suppression rate of 95.7%, with 60% of mice being cured. Our study elucidates a novel and precise strategy of combining Len and US therapy for enhanced HCC immunotherapy.

Precision nanoparticles for drug delivery, cell therapy tracking, and theranostics

Precision nanoparticles for drug delivery, cell therapy tracking, and theranostics

Smart Mesoporous Silica Nanoparticles Loading Curcumin Inhibit Liver Cancer.

Curcumin (CUR) as one of the natural edible pigments is approved by the World Health Organization due to its nontoxic and anticancer effect. However, the utility of CUR is restricted due to its low oral bioavailability. Nanoparticle drug delivery systems like mesoporous silica nanoparticles (MSNs) have been extensively used due to their high specific surface area, high loading rate, and ease of modification. This study developed lactobionic acid (LA)-modified carboxymethyl chitosan (CMCS)-coated MSNs to deliver CUR specifically targeting hepatocellular carcinoma. Among these nanoparticles, LA targets liver cancer cells. CMCS utilizes pH-responsive release of CUR. The LA-CMCS-MSN@CUR (MSN@CUR) were evaluated using several methods, including Fourier transform infrared spectroscopy, transmission electron microscopy, and zeta potential measurements. Liver cellular uptake of MSN@CUR depends on a specific LA receptor-mediated endocytosis mechanism. Additionally, MSN@CUR performed with a better antitumor effect than Cur in H22 orthotopic transplantation of liver cancer and H22 solid tumor mouse models. Treatment with MSN@CUR significantly reduced the protein of VEGF, p-PI3K, and AKT, increased the protein of caspases 3 and 8, ultimately inhibited tumor migration, and promoted apoptosis. This study provides a new path for delivery of natural active ingredients with excellent bioavailability in the antitumor field.

Contemporary and prospective use of azathioprine (AZA) in viral, rheumatic, and dermatological disorders: a review of pharmacogenomic and nanotechnology applications.

Azathioprine (AZA) has been extensively used for immunomodulatory effects in autoimmune disorders and transplantation. This article is proposed to review the contemporary and prospective use of AZA in viral, rheumatic, and dermatological disorders. The primary objective is to draw attention to possible developments in regards to AZA application in recent years, with an emphasis on the use of pharmacogenomics and nanotechnology to improve its efficacy in practice. This study reveals that AZA, having the active metabolites 6-mercaptopurine (6-MP) and 6-thioguanine (6-TG), may be useful in the treatment of systemic lupus erythematosus (SLE), pemphigus vulgaris, and psoriasis. Pharmacogenomic testing of thiopurine methyltransferase (TPMT) and Nudix hydrolase 15 (NUDT15) genotypes minimizes the occurrence of myelosuppression. Furthermore, new formulations of AZA using biocompatible polymers and nanoparticles for drug delivery were reported to improve its efficacy and lower systemic toxicity. This paper aims to establish the multifunctional nature of AZA in modern medicine, thus emphasizing its potential for other applications. Through the combination of pharmacogenomic analysis along with nanotechnology application, AZA makes the promise of enhancing patients' treatment efficacy and extending the stock of medical information available. These advancements offer new possibilities for application of precision medicine and improvements in the use of AZA therapy.

PH-sensitive polymeric hydrogels coated with cobalt ferrite nanoparticles for combined drug delivery as controlled release carriers: fabrication and in-vitro estimation

In this investigation, we produced pH-responsive hydrogels for the controlled release of drugs by graft copolymerizing Gum ghatti and acrylic acid (AA) in an aqueous medium. N, N′-methylene-bis-acrylamide (MBA) and ammonium persulphate (APS) served as cross-linkers during the synthesis process. Our research explores the integration of cobalt ferrite (CoFe2O4) magnetic nanoparticles (CFMNPs) in delivering a combination drug comprising metformin hydrochloride and sodium diclofenac. The diverse applications of CoFe2O4 nanoparticles have driven the exploration of innovative and environmentally sustainable production methods. The development of novel materials for nanoparticle synthesis adheres to the principles of “Green Chemistry” through a co-precipitation technique. Characterization of the cross-linked hydrogels involved Fourier transform infrared spectroscopy (FT-IR) and X-ray diffraction (XRD) analyses. In vitro drug release kinetics were observed under physiological conditions using Ultraviolet–Visible Spectroscopy. The drug-loaded Gg-cl-poly(AA)/CoFe2O4 hydrogels exhibited a sustained drug release profile over 24 h, with significant release occurring at a pH of 4. To comprehend the drug release mechanism, we employed kinetic modeling, encompassing Zero order, First order, Higuchi model, Hixson-Crowell model, and Korsmeyer-Peppas model, for all developed hydrogels. The findings indicated that the drug release mechanism from the hydrogels followed the Korsmeyer-Peppas model. The study concludes that the developed hydrogel offers a promising solution for the controlled administration of metformin hydrochloride and diclofenac sodium.Graphical

Challenges in Exploiting Human H Ferritin Nanoparticles for Drug Delivery: Navigating Physiological Constraints.

Over the past two decades, ferritin has emerged as a promising nanoparticle for drug delivery, catalyzing the development of numerous prototypes capable of encapsulating a wide array of therapeutic agents. These ferritin-based nanoparticles exhibit selectivity for various molecular targets and are distinguished by their potential biocompatibility, unique symmetrical structure, and highly controlled size. The hollow interior of ferritin nanoparticles allows for efficient encapsulation of diverse therapeutic agents, enhancing their delivery and effectiveness. Despite these promising features, the anticipated clinical advancements have yet to be fully realized. As a physiological protein with a central role in both health and disease, ferritin can exert unexpected effects on physiology when employed as a drug delivery system. Many studies have not thoroughly evaluated the pharmacokinetic properties of the ferritin protein shell when administered invivo, overlooking crucial aspects such as biodistribution, clearance, cellular trafficking, and immune response. Addressing these challenges is crucial for achieving the desired transition from bench to bedside. Biodistribution studies need to account for ferritin's natural accumulation in specific organs (liver, spleen, and kidneys), which may lead to off-target effects. Moreover, the mechanisms of clearance and cellular trafficking must be elucidated to optimize the delivery and reduce potential toxicity of ferritin nanoparticles. Additionally, understanding the immune response elicited by exogenous ferritin is essential to mitigate adverse reactions and enhance therapeutic efficacy. A comprehensive understanding of these physiological constraints, along with innovative solutions, is essential to fully realize the therapeutic potential of ferritin nanoparticles paving the way for their successful clinical translation.

Synthesis and Biological Evaluation of Gold Nanoparticles Drug Delivery System as Anti-Rheumatoid Arthritis Agents

Synthesis and Biological Evaluation of Gold Nanoparticles Drug Delivery System as Anti-Rheumatoid Arthritis Agents

A REVIEW HPLC AND UV METHODS FOR THE ESTIMATION OF CIDOFOVIR IN PHARMACEUTICAL DOSAGE FORM

Cidofovir is an antiviral agent primarily used in the treatment of cytomegalovirus (CMV) infections, particularly in immunocompromised patients. This review summarizes the analytical methods developed for estimating Cidofovir, an antiviral used in treating cytomegalovirus (CMV) infections. Emphasis is placed on High-Performance Liquid Chromatography (HPLC) and related techniques, discussing method development, validation, and application across various pharmaceutical dosage forms such as tablets and injectables. The review also highlights the role of HPLC in pharmacokinetic studies and explores recent advancements like nanoparticle drug delivery systems to improve Cidofovir bioavailability. Challenges related to Cidofovir stability, solubility, and renal excretion are also discussed.

Research and development of nano-particles in drug delivery

Nano-technology has revolutionized the pharmaceutical industry, offering a plethora of tools and strategies for drug discovery and development. This review paper delves into the transformative role of nano-materials, particularly nano-particles, in enhancing therapeutic efficacy and overcoming limitations associated with conventional drug delivery systems. We explore how nano-technology facilitates targeted drug delivery, improving drug bio-availability and reducing undesirable side effects. Additionally, the review sheds light on the application of nano-technology in diagnostics and disease imaging, enabling earlier and more accurate disease detection. Furthermore, the paper discusses the ongoing research efforts in utilizing nano-particles for gene therapy and personalized medicine. We address the challenges and considerations surrounding the implementation of nano-technology in pharmaceuticals, including potential safety concerns and regulatory hurdles. Finally, the review concludes by emphasizing the immense potential of nano-technology in shaping the future of pharmaceutical research and development, paving the way for more effective and targeted therapies.

Recent Advances of PDMS In Vitro Biomodels for Flow Visualizations and Measurements: From Macro to Nanoscale Applications

Polydimethylsiloxane (PDMS) has become a popular material in microfluidic and macroscale in vitro models due to its elastomeric properties and versatility. PDMS-based biomodels are widely used in blood flow studies, offering a platform for improving flow models and validating numerical simulations. This review highlights recent advances in bioflow studies conducted using both PDMS microfluidic devices and macroscale biomodels, particularly in replicating physiological environments. PDMS microchannels are used in studies of blood cell deformation under confined conditions, demonstrating the potential to distinguish between healthy and diseased cells. PDMS also plays a critical role in fabricating arterial models from real medical images, including pathological conditions such as aneurysms. Cutting-edge applications, such as nanofluid hemodynamic studies and nanoparticle drug delivery in organ-on-a-chip platforms, represent the latest developments in PDMS research. In addition to these applications, this review critically discusses PDMS properties, fabrication methods, and its expanding role in micro- and nanoscale flow studies.

Review on the application of ginsenosides and their pharmaceutical preparations in the treatment of breast cancer

Ginsenosides, as the main active ingredients of ginseng, have shown great potential in the treatment of breast cancer. Studies have found that many types of ginsenosides, such as PPD ginsenosides Rh2, Rg3, CK and PPT ginsenosides Rg1, Rg2, have inhibitory effects on breast cancer cells. These components can effectively inhibit the development of breast cancer by directly inhibiting the proliferation of cancer cells, inducing apoptosis, enhancing the anticancer ability of NK cells, and remodeling the tumor microenvironment. In addition, the liposome and nanoparticle drug delivery system synthesized by ginsenoside showed great advantages in the application of drug formulations, providing a new strategy for the targeted transportation of antitumor drugs and improving the tumor killing ability. These research results not only provide a new strategy for breast cancer treatment, but also expand the application prospect of ginsenosides in cancer treatment. In the future, with the in-depth research, ginsenosides and their pharmaceutical preparations are expected to play a greater role in the treatment of breast cancer and bring more hope to patients.

Synthesis of Nanoparticles for Drug Delivery in Korea

Purpose: The aim of the study was to assess the synthesis of nanoparticles for drug delivery in Korea. Methodology: This study adopted a desk methodology. A desk study research design is commonly known as secondary data collection. This is basically collecting data from existing resources preferably because of its low cost advantage as compared to a field research. Our current study looked into already published studies and reports as the data was easily accessed through online journals and libraries. Findings: The study indicated that the synthesis of nanoparticles for drug delivery has emerged as a promising strategy to enhance the efficacy and precision of therapeutic interventions. Nanoparticles offer several advantages, such as improved bioavailability, targeted delivery, and controlled release of drugs. Various methods are employed in their synthesis, including chemical reduction, sol-gel processes, and biological methods using natural organisms. These nanoparticles can be engineered to carry a wide range of drugs, including chemotherapeutics, antibiotics, and vaccines. Their small size allows them to navigate biological barriers and deliver drugs directly to specific tissues or cells, reducing side effects and improving treatment outcomes. However, challenges such as scalability, toxicity, and regulatory hurdles remain, necessitating further research to optimize their clinical applications. Implications to Theory, Practice and Policy: Brownian motion theory, nanoscale phenomena theory, thermodynamic theory of nanoparticle stability may be used to anchor future studies on the synthesis of nanoparticles for drug delivery in Korea. Practitioners in the field should prioritize the enhancement of synthesis techniques and the focus on biocompatibility and safety to improve the practical applications of nanoparticle drug delivery systems. To ensure the safe and effective use of nanoparticles in drug delivery, policymakers must establish clear guidelines and regulations governing their application.

Recent advances in surface decoration of nanoparticles in drug delivery

Recent advances in surface decoration of nanoparticles in drug delivery

Lipid-Based Nanoparticles as Drug Delivery System for Modern Therapeutics.

The emergence of lipid-based nanoparticulate systems has significantly reshaped the landscape of drug delivery. This review aims to encapsulate the advancements, challenges, and potential of lipid-based nanoparticulate drug delivery in modern therapeutics. Lipid-based nanoparticles, including liposomes, lipid nanoparticles, and solid lipid nanoparticles, harness the biocompatibility and biodegradability of lipids to encapsulate and deliver a diverse range of therapeutic agents. This platform offers solutions to various drug delivery challenges, such as enhancing drug solubility and bio- availability, achieving controlled and sustained release, targeted delivery, and co-delivery of multi-agents. These nanoparticles have demonstrated potential in overcoming biological barriers, including the blood-brain barrier, mucosal barriers, and cellular barriers, enabling the delivery of drugs to previously inaccessible sites. Biocompatibility and reduced toxicity are intrinsic attributes of lipid-based nanoparticles, minimizing immune responses and systemic toxicity while promoting personalized medicine possibilities. However, challenges in formulation, stability, and regulatory approval underscore the need for ongoing research and innovation in this field.

Synthesis, Characterization and Targeted Drug Delivery of Curcumin-Loaded PLGA Nanoparticles

Background: Nanoparticle-based drug delivery systems have revolutionized therapeutic delivery, offering advantages such as enhanced bioavailability, controlled release, and targeted delivery to diseased tissues. Among these, polymeric nanoparticles, especially those utilizing poly(lactic-co-glycolic acid) (PLGA), have shown significant potential due to their biocompatibility, biodegradability, and stability. Curcumin, a polyphenolic compound with potent anti-inflammatory and anticancer properties, faces clinical limitations due to poor solubility and low bioavailability. Encapsulation in PLGA nanoparticles could enhance curcumin’s therapeutic efficacy by improving stability, controlled release, and targeted delivery. Methods: Curcumin-loaded PLGA nanoparticles were synthesized using a solvent evaporation method. Nanoparticles were characterized using dynamic light scattering (DLS) for size and zeta potential, and scanning electron microscopy (SEM) for morphology. In vitro drug release was assessed using a dialysis method, while cytotoxicity and anti-inflammatory activity were evaluated using MTT and nitric oxide inhibition assays, respectively. Results: DLS analysis revealed an average particle size of 150 ± 10 nm and a zeta potential of -25 ± 2 mV, indicating stability and suitability for therapeutic applications. SEM imaging showed smooth, spherical nanoparticles. Drug release studies displayed a biphasic pattern, with an initial burst followed by sustained release over 72 hours. Cytotoxicity assays demonstrated enhanced anticancer activity of curcumin-loaded nanoparticles compared to free curcumin, with a significantly lower IC50 value (5 ± 0.5 µM versus 15 ± 1.0 µM). Anti-inflammatory studies showed a 60% inhibition of nitric oxide production in LPS-induced macrophages, indicating improved anti-inflammatory efficacy over free curcumin. Conclusion: Curcumin-loaded PLGA nanoparticles show promise as a targeted drug delivery system, with enhanced stability, controlled release, and increased therapeutic efficacy. These findings support further in vivo studies to validate the clinical potential of curcumin nanoparticles in cancer and inflammatory diseases, providing a foundation for advanced therapeutic applications.

GSH-responsive magnetic mesoporous silica nanoparticles for efficient controlled drug delivery in tumor cells

In this study, glutathione (GSH)-responsive magnetic mesoporous silica nanoparticles grafted by disulfide organosilicon (SMNPs) were synthesized, characterized, and evaluated as controlled drug carriers. The nanoparticles exhibited consistent dispersion, considerable drug-loading capacity, and high saturation magnetization. Importantly, they demonstrated the ability to release doxorubicin (DOX) by up to 43% in a reducing tumor microenvironment, highlighting their potential for targeted therapy. In addition, the SMNPs displayed favorable biocompatibility, making them suitable for biomedical applications. Most notably, the SMNPs loaded with DOX effectively killed both HepG2 and HeLa cancer cells, while also showing efficient cellular uptake in HeLa cells. These findings suggest that SMNPs are a promising platform for magnetic-targeted and GSH-responsive delivery of therapeutic agents.

Platelet and Erythrocyte Membranes Coassembled Biomimetic Nanoparticles for Heart Failure Treatment.

Cardiac fibrosis is a prevalent pathological process observed in the progression of numerous cardiovascular diseases and is associated with an increased risk of sudden cardiac death. Although the BRD4 inhibitor JQ1 has powerful antifibrosis properties, its clinical application is extremely limited due to its side effects. There remains an unmet need for effective, safe, and low-cost treatments. Here, we present a multifunctional biomimetic nanoparticle drug delivery system (PM&EM nanoparticles) assembled by platelet membranes and erythrocyte membranes for targeted JQ1 delivery in treating cardiac fibrosis. The platelet membrane endows PM&EM nanoparticles with the ability to target cardiac myofibroblasts and collagen, while the participation of the erythrocyte membrane enhances the long-term circulation ability of the formulated nanoparticles. In addition, PM&EM nanoparticles can deliver sufficient JQ1 with controllable release, achieving excellent antifibrosis effects. Based on these advantages, it is demonstrated in both pressures overloaded induced mouse cardiac fibrosis model and MI-induced mouse cardiac fibrosis that injection of the fusion membrane biomimetic nanodrug carrier system effectively reduced fibroblast activation, collagen secretion, and improved cardiac fibrosis. Moreover, it significantly mitigated the toxic and side effects of long-term JQ1 treatment on the liver, kidney, and intestinal tract. Mechanically, bioinformatics prediction and experimental validation revealed that PM&EM/JQ1 NPs reduced liver and kidney damage via alleviated oxidative stress and mitigated cardiac fibrosis via the activation of oxidative phosphorylation activation. These results highlight the potential value of integrating native platelet and erythrocyte membranes as a multifunctional biomimetic drug delivery system for treating cardiac fibrosis and preventing drug side effects.

Inhibition of bone resorption by nanoparticle drug delivery system

Inhibition of bone resorption by nanoparticle drug delivery system